Device Trial Radar · NCT07823465
RNS System for Drug-Resistant Focal Epilepsy in Adolescents: A Real-World Study
Last checked: Nov 19, 2026Latest source record: Sep 16, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Enrolling by invitation
Enrollment
100
Planned (sponsor's estimate)
Start
Sep 14, 2026
Primary completion
Feb 2027
Study completion May 2027
Sponsor
- Lead sponsor
- NeuroPaceNot on our public-company list
- Sponsor type
- Industry
- Collaborators
- OM1, Inc.
- First posted
- Sep 16, 2026
Design
- Study type
- Observational
- FDA-regulated device
- Yes
- Who can join
- All sexes, from 13 years, up to 19 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The NeuroPace RNS System is FDA-approved for adults with drug-resistant focal epilepsy but is not yet approved for adolescents. This study uses real-world data to evaluate the RNS System's safety and effectiveness in adolescents aged 12 through 17 who have already received the device in routine clinical practice. Data will come from patient-authorized electronic health records and patient-reported outcomes collected through a central study site, not a traditional trial infrastructure. Up to 100 evaluable patients across the United States sites will be enrolled, with results intended to support expansion of the RNS System's approved indication to include this adolescent population.
Conditions
- Focal Epilepsy
- Drug-resistant Focal Epilepsy
Interventions
NeuroPace RNS SystemDevice
The NeuroPace RNS System is an implantable, closed-loop responsive neurostimulation device for drug-resistant focal epilepsy. It continuously monitors electrocorticographic activity through leads placed at one or two seizure foci in the brain and, when it detects the electrical patterns associated with seizure onset, delivers brief, typically imperceptible electrical stimulation directly to that focus to interrupt the seizure before it spreads or produces symptoms.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Rate of Serious Adverse Device Events (SADE)Time frame: Implantation through 84 days post-implant
- Responder Rate (RR50) at 24 monthsTime frame: 24 months post-implant
Locations
1 site in 1 country. Site status is shown where the registry gives one.
OM1's Central Site (Virtual Site)
Waltham, Massachusetts
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.